Skip to search formSkip to main contentSkip to account menu

Zomig

Known as: AscoTop, Zeneca brand of zolmitriptan, AstraZeneca brand of zolmitriptan 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

zolmitriptan
zolmitriptan 2.5 MG Disintegrating Oral Tablet [Zomig]zolmitriptan 5 MG/ACTUAT Nasal Spray [Zomig]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
[Extrahepatic cholestasia during therapy with Zolmitriptan (AscoTop)].
Because of recurrent abdominal pain, jaundice and elevated liver function tests, a sixty-two-year old man had been referred to… 
2004
2004
Cost Considerations of Acute Migraine Treatment
Objective.—To provide medication price data and cost‐reducing strategies for the acute treatment of migraine. 
Review
2004
Review
2004
Zolmitriptan (Zomig®)
New triptans are being released in rapid succession with each addition demonstrating some specific pharmacokinetic properties… 
2004
2004
Which Triptan? - Opportunity for Same or Better Outcomes at Lower Cost
Review
2001
Review
2001
Triptans are all different.
T HERE ARE 4 triptans currently available in theUnitedStates, and 3moreareexpectedto be approved by the Food and Drug… 
1998
1998
Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers
Abstract The novel selective 5-hydroxytryptamine (5-HT)1B/1D agonist, zolmitriptan (Zomig, formerly known as 311C90), has shown… 
1998
1998
Poster Presentations V
Minneapolis Convention Center; Exhibit Hall 3; Thursday, April 30; 7:30 AM-12:00 Noon Posters Displayed; 7:30 AM-12:00 Noon… 
1997
1997
Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with…
Zolmitriptan (Zomig, formerly 311C90) at doses of 0.5-50 mg was administered to 316 unique volunteers in clinical pharmacology… 
1997
1997
The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide
AbstractObjective: This study investigated potential pharmacokinetic or pharmacodynamic interactions between the novel anti… 
1997
1997
Peripheral Vascular Effects and Pharmacokinetics of the Antimigraine Compound, Zolmitriptan, in Combination with Oral Ergotamine in Healthy Volunteers
Members of the new class of antimigraine compounds, 5HT1B/1D agonists, as well as ergotamine, may cause vasoconstriction through… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)